Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX) and Allogene Therapeutics (ALLO)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ardelyx (ARDX – Research Report) and Allogene Therapeutics (ALLO – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ardelyx (ARDX)
TD Cowen analyst Joseph Thome maintained a Buy rating on Ardelyx today and set a price target of $10.00. The company’s shares closed last Thursday at $6.76.
According to TipRanks.com, Thome is a 5-star analyst with an average return of
Ardelyx has an analyst consensus of Strong Buy, with a price target consensus of $11.00.
See Insiders’ Hot Stocks on TipRanks >>
Allogene Therapeutics (ALLO)
William Blair analyst Sami Corwin reiterated a Buy rating on Allogene Therapeutics today. The company’s shares closed last Thursday at $1.48, close to its 52-week low of $1.32.
According to TipRanks.com, Corwin is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Allogene Therapeutics with a $9.00 average price target, which is a 500.0% upside from current levels. In a report issued on January 6, UBS also initiated coverage with a Buy rating on the stock with a $8.00 price target.
